The FSR Pilot Grant program, initiated in 2018, seeks to fund innovative research in both clinical and basic science settings ...

Campbell said avoiding stress and taking great care of her health helped her go into remission Tisha Campbell is speaking out ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

Efzofitimod, the company's first-in-class biologic immunomodulator, is in clinical development for the treatment of interstitial lung diseases or ILD such as pulmonary sarcoidosis. The posters ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

Considering taking supplements to treat sarcoidosis? Below is a list of common natural remedies used to treat or reduce the symptoms of sarcoidosis. Follow the links to read common uses ...

Gender Disparities in the Association of Low Dietary Protein Intake With Congestive Heart Failure: An Analysis of the NHANES Database 2017-2020 Receive the the latest news, research, and presentations ...

BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call was “relatively uneventful” besides an announcement for ...

Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.